Skip to content
DraconiticResearch
Search Sources API
194,220 studies31 sourcesUpdated 40 min ago
PreprintCC BY-NC-NDbioRxiv

Leptin receptor deficiency suppresses gastric tumorigenesis by limiting stromal activation and tumor microenvironment development.

2 more authors
  1. 1Fujita Health University

Abstract

Leptin receptor (LEPR) signaling has been implicated in multiple malignancies; however, its role in gastric tumors remains poorly defined. We previously demonstrated that mice with gastrointestinal epithelial cell-specific deletion of suppressor of cytokine signaling 3 (SOCS3 cKO), a negative feedback regulator of LEPR signaling, develop gastric tumors due to aberrant leptin production and LEPR activation. Here, we demonstrate that concurrent deletion of both Socs3 and Lepr (double knockout; DKO) under the same promoter substantially suppresses gastric tumorigenesis and markedly prolonged survival. Whereas SOCS3 cKO mice exhibited early stromal activation, increased TGF-{beta}1 production, accumulation of cancer-associated fibroblasts (CAFs) and collagen deposition, these tumor-promoting alterations were substantially attenuated in DKO mice. Additionally, DKO mice showed reduced inflammatory cytokine and chemokine signaling, decreased the accumulation of Gr-1+CD11b+ myeloid-derived suppressor cells, and reduced LEPR and TGF-{beta} signaling. Analysis of The Cancer Genome Atlas stomach adenocarcinoma cohort revealed high LEPR expression in the chromosomal instability and genomically stable subtypes, correlating with poor prognosis. Moreover, LEPR expression was mutually exclusive with CLDN18 and ERBB2, two major therapeutic biomarkers, and positively correlated with a CAF-related transcriptional signature. Our findings identify LEPR signaling in epithelial cells as a key driver of gastric tumorigenesis through promotion of stromal activation and tumor microenvironment development. They further highlight LEPR as a promising therapeutic target for patients with gastric cancer who are unlikely to benefit from current ERBB2/HER2- or CLDN18-directed therapies.

Related

  1. Asparagine-linked glycosyltransferase 6 deficiency suppresses tumorigenesis in clear cell renal cell carcinoma by regulating apoptosis and immunotherapy sensitivity
    Zilian Cui, Ning Wang, Zonghai Liu +1
    Chinese Medical JournalPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
  2. Risk-Window Palbociclib Exposure Delays ErbB2-Driven Mammary Tumorigenesis and Suppresses Mammary Epithelial Cell Stemness
    Y. Liu, A. B. Parris, Z. Ma +3
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxiv
  3. Activation of vitamin D signaling suppresses platinum-induced ovarian cancer stem cell plasticity
    T. X. Metcalfe, S. Xanders, R. A. Kinne +6
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  4. Synergistic fluvastatin-nanotherapy suppresses DEPDC1-associated glycolysis and exosomal CCL2 to modulate the immune microenvironment in lung adenocarcinoma.
    Chunhua Li, Xingyu Lyu, Tianyi Kang +10
    Journal of nanobiotechnologyPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCPMC
  5. Hepatic Nnmt Deficiency Alleviates Thiamethoxam-Induced Hepatic Steatosis Via AMPK Activation
    Yilian Liu, Zixuan Meng, Siting Fan +2
    PhenomicsPeer-reviewedLicence not statedFull textPharmacology & toxicologyPMC
BibTeX
@misc{inagakiohara2026leptin,
  title = {{Leptin receptor deficiency suppresses gastric tumorigenesis by limiting stromal activation and tumor microenvironment development.}},
  author = {K. Inagaki-Ohara and D. Motooka and I. Yamanaka and T. Nakayama and S. Abudureyimu and H. Tezuka and E. Sakurai and K. Ushida and T. Kato and S. Nagao and Y. Minokoshi and A. Yoshimura and A. Enomoto and N. Asai},
  howpublished = {bioRxiv},
  year = {2026},
  month = aug,
  doi = {10.64898/2026.08.21.746140},
  url = {https://www.biorxiv.org/content/10.64898/2026.08.21.746140v2},
  note = {CC BY-NC-ND},
}
RIS
TY  - UNPB
TI  - Leptin receptor deficiency suppresses gastric tumorigenesis by limiting stromal activation and tumor microenvironment development.
AU  - K. Inagaki-Ohara
AU  - D. Motooka
AU  - I. Yamanaka
AU  - T. Nakayama
AU  - S. Abudureyimu
AU  - H. Tezuka
AU  - E. Sakurai
AU  - K. Ushida
AU  - T. Kato
AU  - S. Nagao
AU  - Y. Minokoshi
AU  - A. Yoshimura
AU  - A. Enomoto
AU  - N. Asai
PY  - 2026
DA  - 2026/08/21
PB  - bioRxiv
DO  - 10.64898/2026.08.21.746140
UR  - https://www.biorxiv.org/content/10.64898/2026.08.21.746140v2
AB  - Leptin receptor (LEPR) signaling has been implicated in multiple malignancies; however, its role in gastric tumors remains poorly defined. We previously demonstrated that mice with gastrointestinal epithelial cell-specific deletion of suppressor of cytokine signaling 3 (SOCS3 cKO), a negative feedback regulator of LEPR signaling, develop gastric tumors due to aberrant leptin production and LEPR activation. Here, we demonstrate that concurrent deletion of both Socs3 and Lepr (double knockout; DKO) under the same promoter substantially suppresses gastric tumorigenesis and markedly prolonged survival. Whereas SOCS3 cKO mice exhibited early stromal activation, increased TGF-{beta}1 production, accumulation of cancer-associated fibroblasts (CAFs) and collagen deposition, these tumor-promoting alterations were substantially attenuated in DKO mice. Additionally, DKO mice showed reduced inflammatory cytokine and chemokine signaling, decreased the accumulation of Gr-1+CD11b+ myeloid-derived suppressor cells, and reduced LEPR and TGF-{beta} signaling. Analysis of The Cancer Genome Atlas stomach adenocarcinoma cohort revealed high LEPR expression in the chromosomal instability and genomically stable subtypes, correlating with poor prognosis. Moreover, LEPR expression was mutually exclusive with CLDN18 and ERBB2, two major therapeutic biomarkers, and positively correlated with a CAF-related transcriptional signature. Our findings identify LEPR signaling in epithelial cells as a key driver of gastric tumorigenesis through promotion of stromal activation and tumor microenvironment development. They further highlight LEPR as a promising therapeutic target for patients with gastric cancer who are unlikely to benefit from current ERBB2/HER2- or CLDN18-directed therapies.
ER  -